AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal ... Read More
Pfizer’s inotuzumab ozogamicin gains FDA priority review in acute lymphoblastic leukemia
Pfizer Inc. has received a priority review designation from the U.S. Food and Drug Administration (FDA) for its innovative blood cancer drug, inotuzumab ozogamicin. This ... Read More